• Lead drug candidate NYR-BI03 shows strong neuroprotective efficacy in a penetrating traumatic brain injury study
• MRI imaging confirms statistically significant neuroprotection (p = 0.043)
• NYR-BI03 is currently in Phase I clinical trial, evaluating safety and tolerability

Nyrada Inc. (ASX:NYR), a drug discovery and development company specialising in innovative Transient Receptor Potential Canonical (TRPC) ion channel blockers, today announces positive preclinical results demonstrating the efficacy of its lead drug candidate, NYR-BI03, in preventing secondary brain injury following a penetrating traumatic brain injury (TBI). The study was conducted under Nyrada's Cooperative Research and Development Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR). The collaborative study with WRAIR and UNSW Sydney evaluated the efficacy of NYR-BI03 in a rodent model of penetrating TBI, designed to replicate the severe head injuries commonly sustained by military personnel. Using WRAIR's well-established penetrating TBI model, the study involved 28 test animals, which received continuous intravenous infusion of either NYR-BI03 or a vehicle control, over a 48-hour period. UNSW Sydney conducted high-resolution magnetic resonance imaging (MRI) to assess brain tissue integrity at its state-of-the-art small animal imaging facility. The study demonstrated that NYR-BI03 provided a statistically significant level of neuroprotection (p = 0.043; ANOVA). FA MRI analysis identified neuroprotection across six (6) consecutive brain scan levels spanning the region of maximum penetration by the probe. Nyrada's lead drug candidate, NYR-BI03, is currently in a Phase I clinical trial, evaluating its safety and tolerability.

Nyrada remains on schedule with its Phase I study, having completed dosing of the first cohort in March 2025. Final readouts from the trial are expected in Q3 CY2025, as planned.